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Abstract: The objectives of this study were to evaluate the effect of haemodialysis on plasma Cardiac 
Troponin I and cardiac enzymes before and after the dialysis process. Twenty two patients with Chronic Renal 
Failure (CRF) disease who were haemodialyzed at 5th Azar hospital of Gorgan Dialysis Center were recruited 
for this study (2005). The patients do not have coronary heart disease. Plasma cardiac enzymes showed no 
significant difference in the post dialysis group when compared with predialysis. Plasma levels of Cardiac 
Troponin I in 12 haemodialyzed patients were significantly increased in the postdialysis group when 
compared with predialysis, whereas plasma level of Cardiac Troponin I in 10 haemodialyzed patients were 
undetectable (less than 0.1 µg L - 1). The observation of meaningful increasing level of plasma Cardiac Troponin 
I in the haemodialyzed patients after the process of dialysis shows that Cardiac Troponin I is highly specific 
marker for Acute Myocardial Infarction (Alvfl) when compared with other cardiac enzymes and is particularly 
useful for detecting A1.1I in chronic renal failure and haemodialysis patients which can prevent sudden 
cardiovascular abnormality and sudden silent myocardial infarction in these patients 
Key words: Haemodialysis, cardiac enzymes, cardiac Troponin I 
INTRODUCTION 	
Cardiovascular disease is one of the leading cause of 
death in chronic renal failure patients on dialysis, as well 
as leading cause morbidity (Raine et al., 1992). Clinical 
and subclinical myocardial ischaemia are common among 
chronic renal failure patients, both before and during 
dialysis (Foley et al., 1995; Singh et al., 1994). Earlier 
detection of cardiovascular abnormality in these patients 
might allow earlier interventions to reduce morbidity and 
mortality. The prevalence of ischemic heart disease in 
haemodialysis patients in 10-20 times higher than that in 
the general population with 50% mortality due to 
Cardiovascular disease. According to the US Renal Data 
System 42% of patients undergoing haemodialysis have 
had a myocardial infarction or Coronary revasculariztion. 
In addition, the rate of sUIVival after myocardial infarction 
is much lower for haemodialysis patients than for the 
general population (Heeschen et al., 2000). Several 
markers should be used to evaluate Cardiac disease. 
These include total creatine Phosphokinase (CPK), 
Aspartate aminotransferase (AST) and total Lactate 
dehydrogenase (LDH). These markers have poor specifity 
for early detection of Cardiac injuiy because of their wide 
tissue distribution. In recent years, new marker of 
myocardial injwy has been introduced into clinical 
practice. Cardiac Troponin I is specific marker of 
myocardial damage (Bodor et al., 1992; Coudry, 1998). 
Patients with chronic renal failure undergoing 
haemodialysis have a high incidence of Cardiac events 
(Foley et al., 1995) and of false-positive increases in 
myoglobin as well as creatine kinase-1.1B isoenzymes 
(Jaffe et al., 1984; Pierce and Jaffe, 1986). Cardiac Troponin 
I may be increased in these patients without evidence of 
ischemic myocardial damage (McLaurin et al., 1997). In 
haemodialysis patients, the clinical symptoms of Cardiac 
damage are difficult to diagnosis and may be deceptive. In 
addition, high serum concentrations of myoglobin and 
creatine kimse-MB lack specificity (Jaffe et al., 1984). In 
recent years, Cardiac Troponin I has been increasingly 
used in the diagnosis of acute coronary syndromes as 
studies have shown their greater clinical sensitivity over 
creatine kinase-1.1B (D"Costa et al., 1997). 
The aim of this study with the discriminative 
information was to evaluate the effect ofhaemodialysis on 
plasma Cardiac enzymes (total creatine Phosphokinase 
(CPK), Aspartate aminotransferase (AST) and total 
Lactate dehydrogenase (LDH)) and Cardiac Troponin I 
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before and after the dialysis process, to find out the effect 
of haemodialysis on the plasma Cardiac enzymes and 
Cardiac Troponin I. 
MATERIALS AND METHODS 
Twenty two haemodialysis patients who had no 
clinical evidence of myocardial ischaemia, with average 
age 43.54±9.21 years of old (range 21-55). The mean length 
of dialysis for each patients was 3.95±0.14 h with average 
2.27±0.45 times a week. Patients were chosen (14 male, 
8 female) from the patients referred to the Department of 
Haemodialysis Center at 5th Azar hospital in Gorgan 
University of Medical Sciences (2005). The patients 
studied had no evidence of vascular complications, 
including hypertension, coronary artery disease. 
Blood samples were obtained from the patients just 
before and after the process of dialysis in a heparinized 
tubes. Plasma is separated as soon as the blood taken. 
The plasma urea, creatinine, total creatine Phosphokinase 
(CPK), Aspartate amniotransferase (AST) and total 
Lactate dehydrogenase (LDH) were determined for 
haemodialyzed patients before and after the dialysis 
process, using laboratory kit spectrophotometry 
technique (model JENWA Y 6105 UV/VIS) ni the 
laboratory of Biochemistry (Faculty ofMedicnie). Plasma 
Cardiac T roponin I was determined on the VIDAS 
instrument (made in FRANCE) usnig the ELF A (Enzyme­
Linked Fluorescent Assay) technique (Adams et al., 
1993). 
Data was analyzed by student's t- test using SPSS­
11.5 software. p-value less than 0.05 was considered 
significant. 
RESULTS 
In present study we determined the plasma levels of 
total Creatine Phosphokimse (CPK), Aspartate 
aminotransferase (AST) and total Lactate dehydrogenase 
(LDH) and Cardiac Troponni I in 22 patients with Chronic 
Renal Failure. As shown in Table 1 plasma levels of CPK, 
AST and LDH showed no significant difference in the 
postdialysis group when compared with predialysis. 
Plasma level of Cardiac Troponin I (in 12 haemodialyzed 
patients) were significantly increased after the dialysis 
process when compared with the predialysis (p<0.001 ). 
The plasma levels of Cardiac Troponin I in 12 
haemodialyzed patients were significantly increased 
before the dialysis process when compared with normal 
range (p<0.001). The plasma levels of Cardiac Troponinl 
in 10 haemodialyzed patients were undetectable (less than 
0.1 µg L-'). The ranges of >0.1 - <0.8 µg L-' show 
possible myocardial damage. The ranges of >0.8 µg L-l 
show acute myocardial Infarction Cut-off. 
DISCUSSION 
The aim of the present study was to determine and 
compare the plasma level of Cardiac enzymes ( CPK, AST, 
LDH) and Cardiac Troponin I in predicting the outcome of 
haemodialysis patients on regular dialysis. There are a few 
reports describing difference in plasma Cardiac enzymes 
and Cardiac Troponin I in haemodialyzed patients. Some 
of the studies showed an increase while some other 
showed a decrease or no significant differences. The 
results of this study show that the plasma level of CPK, 
AST, LDH no significant differences in postdialysis group 
when compared with predialysis group and Cardiac 
Troponin I was significantly increased in postdialysis 
group when compared with predialysis group. 
Andersen (1980) was studied serum enzyme levels 
(CPK, AST, LDH) ni dialysis patients. The enzyme levels 
were within normal range. 
Study of Singhal et al. (1988) on 105 haemodialysis 
patients showed that plasma level of CPK in 30 
haemodialysis patients increased. 
Study of Nakai et al. (2004) on 61 haemodialysis 
patients showed that plasma level of CPK in 4 
haemodialysis patients increased. 
Study ofChimata eta!. (1994) on 150 haemodialysis 
patients showed that plasma level of AST in 14 
haemodialysis patients decreased. 
In this study we determined the level of plasma CPK, 
AST, LDH ofhaemodialysis patients before and after the 
dialysis process . Our results show no significant 
differences of plasma CPK, AST, LDH ni the postdialysis 
Table 1: The mean and standard deviation of plasma urea, creatinine, total creatine phosphokinase, aspartate aminotransferase total lactate dehydrogenase 
and cardiac Tro onin I 
Test 
Urea (mg dL- 1) 
Creatinine (mg dL-1) 

Total creatine phosphokinase (U L-1) 

Total Lactate dehydrogenase (B-BU mL-1) 

Aspartate aminotransferas (U L-1) 

Cardiac Troponin I (n =12) (µg L-1) 

*p-value was significant 
Fredia sis Postdial sis -value 
123.54±8.51 55.68±7.96 *<0.001 
15.88±3.07 1.96±0.45 *<0.001 
44.33±1.56 43.78±1.27 >0.001 
182.95±7.24 180.68±10.01 >0.001 
33.18±4.20 32.86±2.39 >0.001 
0.21± 0.040 0.57± 0.09 *<0.001 
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group when compared with the predialysis group. Present 
results are in agreement with the groups mentioned in that 
the plasma level of CPK, AST, LDH of haemodialysis 
patients show no significant difference (Andersen, 1980). 
But the results of this study are not in agreement with the 
results of Singhal et al. (1988) and Nakai et al. (2004) 
showing plasma level of CPK in haemodialyzed patients 
were significantly increased after the dialysis process. 
The results of this study also are not in agreement with 
the results of Chirnata et al. (1994) showing plasma level 
of AST in haemodialyzed patients were significantly 
decreased. This situation probably in due to direct 
relation between the blood ofhaemodialysis patients with 
dialysis instrument or reaction of enzymes with some 
uremic substances. 
There are a few studies describing difference in 
plasma Cardiac Troponin I in haemodialyzed patients 
without myocardial ischaemia symptoms. The diagnosis 
of myocardial ischaemia is difficult in haemodialysis 
patients since they are not able to perform adequate 
exercise tests due to limited exercise tolerance. 
Therefore the use of reliable biochemical marker for the 
detection of myocardial damage is essential in these 
patients (Tun et al., 1998). Some studies showed that the 
level of Cardiac Troponin I increased in haemodialyzed 
patients without myocardial ischaemia symptoms 
(Adams et al., 1993; Khan et al., 2001; Beciain et al., 2003; 
Ziebig et al., 2003). Some other studies reported that the 
level of Cardiac Troponin I show no significant 
differences before and after the dialysis process 
in haemodialyzed patients (Tun et al., 1998; 
Donnino et al., 2004). Study of Vayand et al. (2000) 
showed that the plasma level of Cardiac Troponin I 
increased in haemodialyzed patients without myocardial 
ischaemia symptoms. Present results are in agreement 
with the results of studies showing that the plasma level 
of Cardiac Troponin I increased in haemodialyzed 
patients (12 haemodialyzed patients) after the dialysis 
process (Adams et al., 1993; Khan et al., 2001; 
Beciain et al., 2003; Ziebig et al., 2003). But the results of 
this study are not in agreement showing that the plasma 
level of Cardiac Troponin I in haemodialyzed patients 
decreased (Vayand et al., 2000) or showed no significant 
differences (Tun et al., 1998; Donnino et al., 2004) after 
the dialysis process. 
The obsenration of meaningful increasing level of 
plasma Cardiac Troponin I in the haemodialyzed patients 
after the process of dialysis shows that Cardiac Troponin 
I is highly specific marker for Acute Myocardial Infarction 
(A1.1I) when compared with other cardiac enzymes and is 
particularly useful for detecting Alv1I in chronic renal 
failure and haemodialysis patients which can prevent 
sudden cardiovascular abnormality and sudden silent 
myocardial infarction in these patients. 
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